brentuximab vedotin
seagen,takeda
['lymsm']
the study we've all been waiting for! echelon-1 trial rct results. bv-avd demonstrated a significant os benefit over abvd (94% vs 89%) at over 6 years of follow up. time to duke it out, #lymsm! #asco22 
Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ??????